Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial

This was a phase 1 dose-escalation study of ZR202-CoV, a recombinant protein vaccine candidate containing a pre-fusion format of the spike (S)-protein (S-trimer) combined with the dual-adjuvant system of Alum/CpG. A total of 230 participants were screened and 72 healthy adults aged 18–59 years were...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Guang-Wei, Wang, Zhong-Fang, He, Peng, Lan, Qin-Ying, Ni, Ling, Yang, Ya-Zheng, Wang, Chen-Fei, Cui, Ting-Ting, Huang, Li-Li, Yan, Yong-Qiang, Jiang, Zhi-Wei, Yang, Qing, Yu, Bang-Wei, Han, Xi, Chen, Jing-Jing, Yang, Shu-Yuan, Yuan, Lin, Zhou, Ling-Yun, Liu, Ge, Li, Ke, Huang, Zhen, Zhao, Jin-Cun, Hu, Zhong-Yu, Xie, Zhi-Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644802/
https://www.ncbi.nlm.nih.gov/pubmed/37881130
http://dx.doi.org/10.1080/21645515.2023.2262635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644802/
https://www.ncbi.nlm.nih.gov/pubmed/37881130
http://dx.doi.org/10.1080/21645515.2023.2262635

Ejemplares similares